Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized study of ABBV-400 plus fluorouracil, folinic acid, and bevacizumab in previously treated unresectable metastatic colorectal cancer
MOH_2023-09-04_012910Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Sep 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of telisotuzumab adizutecan in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (7 arms), sponsored by AbbVie Inc. Primary endpoints: Safety, Antitumor activity and 1 more. Started Sep 2023; status: recruiting.
02
Drugs
telisotuzumab adizutecan
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on MOH_2023-09-04_012910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-09-04_012910.